1357945-27-7

Basic information

• Product Name: 3-b]pyridine
• Synonyms: 5-chloro-3-iodo-1H-pyrazolo[4;5-Chloro-3-iodo-1H-pyrazolo[4,3-b]pyridine
• CAS NO: 1357945-27-7
• Molecular Formula: C₆H₃ClIN₃
• Molecular Weight: 279.46559
• Mol File: 1357945-27-7.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 404.9±40.0 °C(Predicted)
• Appearance: /
• Density: 2.284±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.79±0.40(Predicted)
• CAS DataBase Reference: 3-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-b]pyridine(1357945-27-7)
• EPA Substance Registry System: 3-b]pyridine(1357945-27-7)

Safety Data

• Hazardous Substances Data: 1357945-27-7(Hazardous Substances Data)

Usage

Uses

5-Chloro-3-iodo-1H-pyrazolo[4,3-b]pyridine is a reactant used for the synthesis of Benzothiazol-6-ylacetic acid derivatives as anti-HIV.

Upstream product

• 94220-45-8 5-chloro-1H-pyrazolo[4,3-b]pyridine 
• 516-12-1 N-iodo-succinimide 
• 164666-68-6 3-amino-6-chloro-2-methylpyridine 
• 76006-08-1 5-chloro-1H-pyrazolo<3,4-c>pyridine 

Relevant articles and documents

BICYCLIC HETEROCYCLES AS FGFR INHIBITORS

The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of FGFR3-associated diseases such as cancer.

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

INDAZOLE CONTAINING MACROCYCLES AND THERAPEUTIC USES THEREOF

Indazole macrocycle compounds of formula (I) for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole macrocycle compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. Formula (I)